Fig. 2: Radiographic response to FX-909 in patients with advanced UC.
From: A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial
Waterfall plot of best percentage change from baseline in SLD in measurable radiographic disease for all patients with advanced UC with measurable disease and at least one post-baseline scan (N = 39, excluding one patient with clinical progression during cycle 1 and no post-baseline scan completed).
